



# FINANCIAL TEAR SHEET

## Corporate Profile

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

## Primary IR Contact

Matthew Duffy  
LifeSci Advisors  
Phone: 212-915-0685  
E-mail:  
Matthew@lifesciadvisors.com

## Stock Information

PTX.O (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$2.61
Change (%)	▲ 0.02 (0.77%)
Volume	113,321
52 Week Low	\$1.83
Market Cap	\$28,791,577
Rolling EPS	-17.00
PE Ratio	0
Shares Outstanding	11,116,439

Data as of 08/17/17 3:59 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Recent Press Releases & Upcoming Events

July 27, 2017 - 4:03 p.m.

Pernix Therapeutics Reports Second Quarter  
2017 Financial Results and Provides Business  
Update

July 20, 2017 - 4:54 p.m.

Pernix Commences Refinancing Transactions to  
Fortify Balance Sheet

July 20, 2017 - 4:53 p.m.

Pernix Therapeutics Pre-Announces  
Certain Preliminary Second Quarter 2017  
Financial Results

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
08/15/17	8-K
08/11/17	EFFECT
08/09/17	4
08/09/17	4

## Corporate Governance

John Sedor	Chairman of the Board and CEO
Graham Miao	President and CFO
Kenneth R. Piña	Senior Vice President, Chief Legal & Compliance Officer and Corporate Secretary
Cindy Lehrer	Vice President, Human Resources
George P. Jones	Vice President of Sales and Marketing
Angus Smith	Vice President, Business Development & Strategic Planning